Indomethacin: Difference between revisions
(Add dynamic SMW Indications by Condition table (auto-populated from disease pages via MedicationDose template)) |
(Switch SMW query from broadtable to table format for better layout with TOC) |
||
| (One intermediate revision by the same user not shown) | |||
| Line 114: | Line 114: | ||
|?Has Route=Route | |?Has Route=Route | ||
|?Has Population=Population | |?Has Population=Population | ||
|format= | |format=table | ||
|headers=plain | |headers=plain | ||
| | |mainlabel=- | ||
|sort=Has Indication | |sort=Has Indication | ||
|limit=50 | |limit=50 | ||
Latest revision as of 21:56, 20 March 2026
General
- Type: NSAID
- Dosage Forms: PO (Generic in 25 and 50mg tabs)
- Common Trade Names: Indocin
Adult Dosing
Preterm labor/Tocolysis
- 50-100mg loading dose, 25mg q4-6 hrs for 48 hrs
- 25mg PO BID-TID, max 200mg/day, give with food
- 50mg PO TID, taper dose rapidly
- 25mg PO bid-tid, max 200mg/day
- 25mg PO bid-tid, max 200mg/day
Pediatric Dosing
- <48 hour old: start 0.2mg/kg IV x 1, then 0.1mg/kg q12-24h x 2
- 2-7 days old: Start 0.2mg/kg IV x 1, then 0.2mg/kg q12-24h x 2
- > 7 days old: Start 0.2mg/kg IV x 1, then 0.25mg/kg q12-24h x 2
- 1-2mg/kg/day PO divided BID-QID, max 4mg/kg/day up to 150-200mg/day
Special Populations
- Pregnancy Rating: B
- Lactation: probably safe
- Renal Dosing
- Adult: no adjustment
- Pediatric: no adjustment
- Hepatic Dosing
- Adult: not defined, caution advised if hepatic impairment
- Pediatric: not defined, caution advised if hepatic impairment
Contraindications
- Allergy to class/drug
- ASA or NSAID-induced ashtma or urticaria
- Pregnancy 3rd trimester
- Infection, untreated (neonates)
- Active bleeding (neonates)
- Thrombocytopenia (neonates)
- Coagulation Disorder (neonates)
- Necrotizing enterocolitis (neonates)
- renal impairment, significant (neonates)
- Pulmonary atresia (neonates)
- Tetralogy of Fallot, severe (neonates)
- Aortic coarctation, severe (neonates)
- CABG surgery period use
- caution if cardiovascular disease
- caution if hypertension
- caution if CHF
- caution if fluid retention
- caution if GI bleeding or ulcer history
- caution in elderly patients
- caution if dehydration
- caution if sepsis
- caution if asthma
- caution if prolonged use
Adverse Reactions
Serious
- pulmonary hemorrhage (neonates)
- GI bleeding
- GI perforation/ulcer
- MI
- Stroke
- Thromboembolism
- hypertension
- CHF
- Renal Papillary Necrosis
- Acute Renal Failure
- Hepatotoxicity
- Steven-Johnson syndrome
- Anemia
- Thrombocytopenia, neonates
- hyponatremia (neonates)
- hyperkalemia (neonates)
Common
- dyspepsia
- nausea
- abdominal pain
- constipation
- headache
- dizziness
- rash
- ALT,AST elevation
- fluid retention
- tinnitus
- corneal deposits
- photosensitivity
Pharmacology
- Half-life: 4.5 hours, 12-21 hours in neonates
- Metabolism: Liver; CYP450, 2C9 substrate
- Excretion: urine 60%, feces 33%
- Mechanism of Action: exact mechanism unknown, inhibits cyclooxygenase, reducing prostaglandin and thromboxane synthesis
Indications by Condition
The following table is automatically generated from disease/condition pages across WikEM.
| Indication | Dose | Context | Route | Population |
|---|---|---|---|---|
| Acute pain management | 25-50 mg PO q12h or 100 mg PR q24h | Non-opioid analgesic (NSAID) | PO/PR | Adult |
| Gout and pseudogout | 50mg TID x 3-5 days | First-line NSAID option for acute gout | PO | Adult |
| Patent ductus arteriosus | 0.2mg/kg IV x1, then 0.1-0.25mg/kg q12-24h x2 (dose varies by age) | Medical closure, first 10-14 days of life | IV | Pediatric |
| Preterm labor | 50-100mg load, then 25mg q4-6hr x 48hr | Tocolytic; avoid >32 weeks gestation (risk of ductus arteriosus closure) | PO/PR | Adult |